Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunoadsorption Therapy in Childhood Anti-NMDAR Encephalitis
NCT03274375Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2021
- Primary completion
- Oct 2023
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in Anti-N-methyl-D-aspartate receptor encephalitis, sponsored by Assistance publique - Hôpitaux de Paris. Started Jun 2021; status: completed.
02
Drugs
rituximab
03
Conditions
Anti-N-methyl-D-aspartate receptor encephalitis
Beyond the preview
Go deeper on NCT03274375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03274375.